Ulisse Biomed Statistics

Total Valuation

Ulisse Biomed has a market cap or net worth of EUR 18.66 million. The enterprise value is 17.86 million.

Market Cap	18.66M
Enterprise Value	17.86M

Important Dates

The last earnings date was Friday, March 28, 2025.

Earnings Date	Mar 28, 2025
Ex-Dividend Date	n/a

Share Statistics

Ulisse Biomed has 24.48 million shares outstanding.

Current Share Class	n/a
Shares Outstanding	24.48M
Shares Change (YoY)	n/a
Shares Change (QoQ)	n/a
Owned by Insiders (%)	n/a
Owned by Institutions (%)	n/a
Float	n/a

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	39.47
PB Ratio	0.67
P/TBV Ratio	4.77
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	-2.56
EV / Sales	42.44
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 2.36, with a Debt / Equity ratio of 0.02.

Current Ratio	2.36
Quick Ratio	1.43
Debt / Equity	0.02
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	-471.58

Financial Efficiency

Return on equity (ROE) is -46.78% and return on invested capital (ROIC) is -29.40%.

Return on Equity (ROE)	-46.78%
Return on Assets (ROA)	-25.89%
Return on Invested Capital (ROIC)	-29.40%
Return on Capital Employed (ROCE)	-26.86%
Revenue Per Employee	52,616
Profits Per Employee	-870,816
Employee Count	10
Asset Turnover	0.02
Inventory Turnover	1.73

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -47.59% in the last 52 weeks. The beta is 0.70, so Ulisse Biomed's price volatility has been lower than the market average.

Beta (5Y)	0.70
52-Week Price Change	-47.59%
50-Day Moving Average	0.82
200-Day Moving Average	0.91
Relative Strength Index (RSI)	42.66
Average Volume (20 Days)	19,800

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Ulisse Biomed had revenue of EUR 420,924 and -6.97 million in losses. Loss per share was -0.32.

Revenue	420,924
Gross Profit	-1.45M
Operating Income	-7.11M
Pretax Income	-6.97M
Net Income	-6.97M
EBITDA	-6.33M
EBIT	-7.11M
Loss Per Share	-0.32

Full Income Statement

Balance Sheet

The company has 1.23 million in cash and 434,773 in debt, giving a net cash position of 790,598 or 0.03 per share.

Cash & Cash Equivalents	1.23M
Total Debt	434,773
Net Cash	790,598
Net Cash Per Share	0.03
Equity (Book Value)	24.74M
Book Value Per Share	1.13
Working Capital	2.88M

Full Balance Sheet

Cash Flow

Operating Cash Flow	n/a
Capital Expenditures	n/a
Free Cash Flow	n/a
FCF Per Share	n/a

Full Cash Flow Statement

Margins

Gross Margin	n/a
Operating Margin	-1,689.04%
Pretax Margin	-1,655.06%
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

Ulisse Biomed does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	n/a
Shareholder Yield	n/a
Earnings Yield	-37.34%
FCF Yield	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Ulisse Biomed has an Altman Z-Score of 2.14. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	2.14
Piotroski F-Score	n/a